spacer
home > ict > summer 2018 > restricting remedies
PUBLICATIONS
International Clinical Trials

Restricting Remedies

Herbal medicine has been practised in many countries for centuries. The 2004 European Traditional Herbal Medicinal Products Directive took full effect in the UK in 2011. This legislation effectively banned the importation and sale of large-scale manufactured herbal medicine products and severely limited the scope of some herbal practitioners to continue practising. At present, under UK law, a herbal practitioner is permitted to see individual patients, offer diagnoses, and prepare herbal treatments on their own premises, as long as these preparations do not contain banned or restricted substances. Thus, where ‘herbal’ products derived from the cannabis plant are concerned because they are banned or restricted substances, they cannot be prescribed by herbal practitioners. Herein lies the problem of the use of cannabis oil for the treatment of rare forms of childhood epilepsy, which has gripped the media of late.

In a review into cannabis-related medicinal products, the UK’s Chief Medical Officer and Advisor, Professor Dame Sally Davies, has concluded that evidence shows the therapeutic benefit of cannabis-based medicines for some conditions. The finding has prompted Home Secretary Sajid Javid to commission the second part of the UK’s review into cannabisrelated medicinal products, led by an independent advisory committee. However, prior to this review, cannabis oil had been prescribed to a young boy with epilepsy on the NHS. Reports have called this the “first case of its kind” in the UK.

Cannabis oil is a medicine containing a part of the cannabis plant called cannabidiol (CBD). It does not contain the ‘psychoactive’ part of cannabis – the part that causes the feeling of being high. Last year, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) classed CBD as a medicine in the UK and not a herbal. The agency has thus said that CBD products are required to be licensed, meaning they “have to meet safety, quality and efficacy standards,” as would be the case for any therapeutic drug prescribed in the UK.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers
 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement